Patents by Inventor Jinhe Pan

Jinhe Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 18/19F-labelled compounds which target the prostate specific membrane antigen
    Patent number: 10882871
    Abstract: This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 5, 2021
    Inventors: Francois Benard, Kuo-shyan Lin, David Perrin, Zhibo Liu, Hsiou-ting Kuo, Jinhe Pan, Aron Roxin, Mathieu Lepage
  • 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN
    Publication number: 20190010171
    Abstract: This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
    Type: Application
    Filed: January 10, 2017
    Publication date: January 10, 2019
    Inventors: Francois BENARD, Kuo-shyan LIN, David PERRIN, Zhibo LIU, Hsiou-ting KUO, Jinhe PAN, Aron ROXIN, Mathieu LEPAGE
  • Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders
    Patent number: 10039846
    Abstract: Bradykinin B1 receptor (B1R) targeting peptides and compounds are radiolabelled with radioisotopes that are suitable for imaging and/or radiotherapy. The radiolabelled peptides and compounds have utility in imaging tissues expressing or overexpressing B1R and/or treating diseases or conditions in which B1R is expressed or overexpressed, including cancer.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 7, 2018
    Assignee: BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Kuo-shyan Lin, Francois Benard, Jinhe Pan, Felix Mesak, Zhengxing Zhang
  • COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS
    Publication number: 20150238641
    Abstract: Bradykinin B1 receptor (B1R) targeting peptides and compounds are radiolabelled with radioisotopes that are suit-able for imaging and/or radiotherapy. Said radiolabelled peptides and compounds have utility in imaging tissues expressing or over expressing B1R and/or treating diseases or conditions in which B1R is expressed or overexpressed, including cancer.
    Type: Application
    Filed: September 13, 2013
    Publication date: August 27, 2015
    Inventors: Kuo-shyan Lin, Francois Benard, Jinhe Pan, Felix Mesak, Zhengxing Zhang